Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
1 selected
)
Type
Guidance (317)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (17)
Medical technologies guidance (7)
Technology appraisal guidance (289)
Apply filters
Showing 291 to 300 of 317
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]
Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781
Technology appraisal guidance
Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease
Interventional procedures guidance
Upadacitinib for treating giant cell arteritis [ID6299]
Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Technology appraisal guidance
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutation in the CFTR gene in people aged 6 years and over TS ID 11919
Technology appraisal guidance
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over [ID6358]
Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]
Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TS ID 11950
Technology appraisal guidance
Previous page
1
…
28
29
Current page
30
31
32
Page
30
of
32
Next page
Results per page
10
25
50
All
Back to top